Gemoflaxin: A broad-spectrum oral quinolone for treatment of respiratory and urinary tract infections

Formulary

Volumn 35, Issue 12, 2000, Pages 961-968

  Lomaestro, B M ^a  

^a Va Stratton Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; CALCIUM CARBONATE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OMEPRAZOLE; TROVAFLOXACIN;

ADVERSE DRUG REACTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CHRONIC BRONCHITIS; CLINICAL TRIAL; DRUG HALF LIFE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; URINARY TRACT INFECTION;

EID: 0033636358     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Antipneumococcal activities of gemifloxacin compared to those of nine other agents
2. Practice guidelines for the management of community-acquired pneumonia in adults
3. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin
4. Activities and postantibiotic effects of germifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis
5. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
6. In vitro and in vivo evaluations of LB20300, a new fluoronaphthyridone
7. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA
8. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae
9. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci
10. In vitro activity of gemifloxacin (SB 265805) against anaerobes
11. Comparative in vitro activity of gemifloxacin
12. Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria
13. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers
14. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers
15. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following once-daily repeat oral 320 mg doses to healthy elderly volunteers
16. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
17. 24/MIC for 6 fluoroquinolones against Streptococcus pneumoniae (SP) with survival and bactericidal activity in an animal model
18. Pharmacodynamics of levofloxacin A new paradigm for early clinical trials
19. Efficacy of once daily gemifloxacin in the treatment of community-acquired pneumonia
20. Effective short-course therapy of acute exacerbation of chronic bronchitis (AECB) with once daily gemifloxacin
21. Efficacy of once daily gemifloxacin (GEMI) for 5 days compared with twice daily clarithromycin (CLARI) for 7 days in the treatment of AECB
22. Efficacy of 7 days of gemifloxacin in patients with acute bacterial sinusitis (ABS)
23. Efficacy of once daily gemifloxacin for 7 days compared with cefuroxime twice daily for 10 days in the treatment of acute bacterial sinusitis
24. Effective short-course treatment of acute uncomplicated UTI (uncomplicated cystitis) with once daily gemifloxacin
25. Effective once daily gemifloxacin for the therapy of complicated UTI and pyelonephritis
26. Safety of gemifloxacin in adult patients with respiratory and urinary tract infections
27. Safety of gemafloxacin in patients aged ≥65 years with respiratory and urinary tract infections
28. Assessment of the effect of gemifloxacin on QTc interval in healthy volunteers
29. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers
30. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers
31. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers
32. Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin
33. Effect of Maalox® on the bioavailability of oral gemifloxacin in healthy volunteers
34. Effect of calcium carbonate on the bioavailability of gemifloxacin in healthy volunteers
35. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers
36. Comparative in vitro activity of gemifloxacin (SB-265805), a new fluoroquinolone, against respiratory tract pathogens
37. Antimicrobial spectrum of gatifloxacin in the SENTRY program
38. Comparative in vitro activity of six fluoroquinolones against 5316 clinical isolates
39. Global resistance patterns of quinolones, macrolides and β-lactams from a multi-center, multi-country study of >9,000 isolates. The gemifloxacin surveillance study
40. Comparative in vitro activity of gatifloxacin
41. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae
42. Antibacterial activity of gatifloxacin (GAT) against Enterobacteriaceae and nonfermenting gram-negative bacteria
43. Comparative activity of 7 quinolones against non-glucose fermenting gramnegative bacilli isolated from cancer patients